BRPI0920647A2 - composto de piperidina e composição farmacêutica e respectivo uso e método de tratamento de doença gastrointestinal em mamífero - Google Patents
composto de piperidina e composição farmacêutica e respectivo uso e método de tratamento de doença gastrointestinal em mamíferoInfo
- Publication number
- BRPI0920647A2 BRPI0920647A2 BRPI0920647A BRPI0920647A BRPI0920647A2 BR PI0920647 A2 BRPI0920647 A2 BR PI0920647A2 BR PI0920647 A BRPI0920647 A BR PI0920647A BR PI0920647 A BRPI0920647 A BR PI0920647A BR PI0920647 A2 BRPI0920647 A2 BR PI0920647A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammals
- pharmaceutical composition
- piperidine compound
- gastrointestinal disease
- treating gastrointestinal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10507008P | 2008-10-14 | 2008-10-14 | |
| US61/105,070 | 2008-10-14 | ||
| PCT/KR2009/005863 WO2010044585A2 (en) | 2008-10-14 | 2009-10-13 | Piperidine compounds, pharmaceutical composition comprising the same and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0920647A2 true BRPI0920647A2 (pt) | 2016-04-19 |
| BRPI0920647B1 BRPI0920647B1 (pt) | 2021-10-13 |
Family
ID=42099444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920647-7A BRPI0920647B1 (pt) | 2008-10-14 | 2009-10-13 | Composto de piperidina, composição farmacêutica e respectivos usos |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8642772B2 (pt) |
| EP (1) | EP2358702B1 (pt) |
| JP (1) | JP5555243B2 (pt) |
| KR (1) | KR101683222B1 (pt) |
| CN (3) | CN102186840B (pt) |
| AU (1) | AU2009304054B2 (pt) |
| BR (1) | BRPI0920647B1 (pt) |
| CA (1) | CA2738609C (pt) |
| ES (1) | ES2428101T3 (pt) |
| MX (1) | MX2011002091A (pt) |
| PL (1) | PL2358702T3 (pt) |
| RU (1) | RU2514827C2 (pt) |
| WO (1) | WO2010044585A2 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102026988B (zh) * | 2008-06-05 | 2013-07-03 | 爱思开生物制药株式会社 | 3-取代的丙胺化合物 |
| US8101642B2 (en) | 2008-06-05 | 2012-01-24 | Sk Biopharmaceuticals Co., Ltd. | 3-substituted propanamine compounds |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496228B1 (en) | 2009-11-06 | 2014-01-15 | SK Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| KR101783633B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 섬유근육통 증후군의 치료 방법 |
| KR101180174B1 (ko) * | 2010-04-23 | 2012-09-05 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| JP6392344B2 (ja) * | 2013-07-25 | 2018-09-19 | ドン−ア エスティ カンパニー リミテッド | ベンズアミド誘導体の製造方法、その製造に使用される新規な中間体及び該中間体の製造方法 |
| WO2025211748A1 (ko) * | 2024-04-03 | 2025-10-09 | 에스케이바이오팜 주식회사 | 5-ht4 수용체 작용제의 glp-1 수용체 작용제에 의해 유발된 위장관 운동 장애를 예방, 경감 또는 치료하기 위한 용도 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0774460A1 (en) | 1994-03-30 | 1997-05-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compound and use thereof as medicine |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| IT1275903B1 (it) | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| EP0873990A1 (en) * | 1995-09-22 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
| GB9523526D0 (en) * | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| TW548103B (en) | 1997-07-11 | 2003-08-21 | Janssen Pharmaceutica Nv | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| HUP0101511A3 (en) | 1998-04-28 | 2002-12-28 | Dainippon Pharmaceutical Co | 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| CA2443108A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| JP2004537526A (ja) * | 2001-06-12 | 2004-12-16 | メルク エンド カムパニー インコーポレーテッド | 片頭痛の治療又は予防用nr2b受容体拮抗薬 |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| BR0314584A (pt) | 2002-09-20 | 2005-08-09 | Pfizer | Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4 |
| WO2004094418A1 (en) | 2003-04-21 | 2004-11-04 | Pfizer Inc. | Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity |
| ATE539077T1 (de) | 2003-09-03 | 2012-01-15 | Pfizer | Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor |
| CA2545092C (en) | 2003-11-24 | 2010-08-17 | Pfizer Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
| DK1701951T3 (da) * | 2003-12-23 | 2010-06-07 | Serodus As | Modulatorer af perifere 5-HT receptorer |
| DE602005005167T2 (de) * | 2004-01-29 | 2009-04-30 | Pfizer Inc. | 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| BRPI0512046A (pt) | 2004-06-15 | 2008-02-06 | Pfizer | derivados de ácido benzimidazolona carboxìlico |
| JP2008509088A (ja) * | 2004-09-02 | 2008-03-27 | ファイザー株式会社 | ベンズイミダゾロンカルボン酸誘導体 |
| NZ556627A (en) | 2005-02-22 | 2010-09-30 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| BRPI0608148A2 (pt) | 2005-04-08 | 2009-11-10 | Pfizer Prod Inc | [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso |
| US20080085915A1 (en) | 2006-06-23 | 2008-04-10 | Cyrus Becker | Compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
-
2009
- 2009-10-09 US US12/576,494 patent/US8642772B2/en active Active
- 2009-10-13 CN CN200980140895.6A patent/CN102186840B/zh active Active
- 2009-10-13 CA CA2738609A patent/CA2738609C/en active Active
- 2009-10-13 CN CN201610090231.5A patent/CN105646331B/zh active Active
- 2009-10-13 JP JP2011532014A patent/JP5555243B2/ja active Active
- 2009-10-13 RU RU2011109435/04A patent/RU2514827C2/ru active
- 2009-10-13 BR BRPI0920647-7A patent/BRPI0920647B1/pt active IP Right Grant
- 2009-10-13 EP EP09820735.0A patent/EP2358702B1/en active Active
- 2009-10-13 CN CN201410234573.0A patent/CN103980184B/zh active Active
- 2009-10-13 ES ES09820735T patent/ES2428101T3/es active Active
- 2009-10-13 WO PCT/KR2009/005863 patent/WO2010044585A2/en not_active Ceased
- 2009-10-13 KR KR1020117006210A patent/KR101683222B1/ko active Active
- 2009-10-13 AU AU2009304054A patent/AU2009304054B2/en active Active
- 2009-10-13 PL PL09820735T patent/PL2358702T3/pl unknown
- 2009-10-13 MX MX2011002091A patent/MX2011002091A/es active IP Right Grant
-
2014
- 2014-01-17 US US14/158,517 patent/US9593102B2/en active Active
-
2016
- 2016-08-26 US US15/248,872 patent/US9676718B2/en active Active
-
2017
- 2017-06-09 US US15/618,252 patent/US10144709B2/en active Active
-
2018
- 2018-11-29 US US16/204,364 patent/US20190092727A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0920647A2 (pt) | composto de piperidina e composição farmacêutica e respectivo uso e método de tratamento de doença gastrointestinal em mamífero | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| IL252119B (en) | Improved cell composition and methods of making the same | |
| BRPI0906980A2 (pt) | Composição de derivados e maleatados | |
| BRPI0905715A2 (pt) | Composição farmacêutica e kit de componentes | |
| FI20090094L (fi) | Olmesartaanimedoksomiilin ja amlodipiinin kiinteä annostusmuoto | |
| SMT201400181B (it) | Composizioni per vasocostrizione e metodi d'uso | |
| BRPI0912703A2 (pt) | composições imuno-moduladoras e métodos para uso dessas | |
| BRPI0819232A2 (pt) | composto heterocíclico e composição farmacêutica do mesmo | |
| BRPI0908132A2 (pt) | Composto de benzodiazepina e composição farmacêutica | |
| BRPI0918206A2 (pt) | derivados de animoéster e composição medicinal destes | |
| EP2154966A4 (en) | BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF | |
| FI20070935L (fi) | Koostumus ja menetelmä puun käsittelemiseksi | |
| BRPI0907109A2 (pt) | lenço dental e método | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| EP2236149A4 (en) | MEDICAL COMPOSITION | |
| ATE465229T1 (de) | Textilbehandlungsverfahren und zusammensetzung | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| EP2298365A4 (en) | MEDICAL COMPOSITION AND MEDICAL KIT | |
| FI20075431L (fi) | Nanopartikkeleihin perustuvat rakenteet ja menetelmät niiden valmistamiseksi | |
| BRPI0907706A2 (pt) | Composto, uso do dito composto e composição farmacéutica compreendendo o dito composto | |
| BRPI0912171A2 (pt) | composição farmacêutica | |
| BRPI0820260A2 (pt) | Composição anti-helmíntica e uso da composição | |
| FI20070395L (fi) | Fotokatalyyttisesti aktiivinen koostumus ja menetelmä sen valmistamiseksi | |
| EP2046368A4 (en) | ANTI-COCAINE COMPOSITIONS AND TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B25A | Requested transfer of rights approved |
Owner name: SK BIOPHARMACEUTICALS CO. , LTD. (KR) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: PARA QUE A PETICAO NO 870160020204 DE 13/05/2016 POSSA SER ACATADA COMO PETICAO DE RECURSO CONTRA PERDA DE PRIORIDADE, O DEPOSITANTE DEVERA REALIZAR O PAGAMENTO DO VALOR DA RETRIBUICAO DEVIDA.(6.7) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |